TGA, 23 December 2025 – Australia’s Therapeutic Goods Administration (TGA) has kicked off a significant overhaul of its medical device conformity assessment procedures, a shift that could redefine how medical device companies register, test, and monitor their products locally. The draft proposals aim to align Australia’s system with global benchmarks like the EU MDR/IVDR and MDSAP, simplify assessments, and strengthen safety and market surveillance. Here’s what you need to know if your products are sold or will be sold in Australia.
WHY MEDICAL DEVICE CONFORMITY ASSESSMENT PROCEDURES MATTER NOW
The TGA’s proposed revisions are part of a broader regulatory modernization effort to reduce duplication, improve alignment with international best practices, and ultimately make the Australian market more predictable for global manufacturers. If adopted, these changes will set new expectations for quality management, design controls, post-market data collection and device classification.
KEY PROPOSED CHANGES TO MEDICAL DEVICE CONFORMITY ASSESSMENT PROCEDURES AND WHAT THEY MEAN FOR YOU
International Harmonization
Australia’s current conformity assessment pathways are fragmented and partly outdated. The TGA intends to:
- Remove rarely used procedures like Type Examination and Product Verification.
- Align more closely with European MDR/IVDR standards and MDSAP QMS expectations.
Impact:
Manufacturers already compliant with EU and MDSAP systems may see reduced redundancy and smoother clearances in Australia. But companies relying on older pathways will need to adapt documentation and processes.
Simplification of Assessment Routes
The proposal streamlines multiple assessment routes, creating a clearer pathway for most devices while reducing administrative complexity.
Impact:
Expect faster review times and reduced administrative cost – but also fewer alternative pathways if your device doesn’t fit the “standard” mold. This places more emphasis on strong upfront regulatory strategy.
Stronger Design & Development Controls
Under the draft, design and development controls will become core to conformity assessment, meaning manufacturers must demonstrate robust planning and control from concept through validation.
Impact:
Risk management, design traceability, and tech documentation must be tighter than before especially for high‑risk or software‑driven products.
Enhanced Post‑Market Surveillance
The TGA proposals significantly expand expectations for monitoring devices after market entry including:
- Post‑market clinical data gathering
- Performance follow‑up
- Reporting safety issues and updating risk assessments
Impact:
Manufacturers must build ongoing surveillance into their quality systems and be prepared to justify safety and performance with real‑world data not just pre‑market testing.
Reclassification of Some Devices
Notably, the draft suggests upgrading reusable surgical instruments from Class I to Class IIa.
Impact:
Manufacturers of surgical instruments will face more rigorous conformity assessment and documentation expectations going forward. This aligns Australia with higher regulatory scrutiny seen in other markets.
PROPOSED IMPLEMENTATION TIMELINE
Phase | What Happens | Expected Effect |
Draft Consultation | Industry and stakeholders review proposals | Feedback influences final rules |
Final Rulemaking | TGA publishes the new framework | Manufacturers start transition planning |
Transitional Period | Grace period to update systems | Companies align to new requirements |
(Note: This timeline is indicative based on the proposal process; final dates will depend on TGA decisions.)
WHAT MANUFACTURERS SHOULD DO NOW
Review Your Quality Systems
Ensure your QMS aligns with international standards (ISO 13485 / MDSAP) and includes design and development controls, risk management, and clinical evaluation documentation.
Strengthen Post‑Market Plans
If your product is already marketed in Australia, prepare to scale post‑market surveillance activities well beyond basic vigilance reporting.
Assess Device Classification
Products previously classified as low‑risk (especially reusable instruments) may require redesign of technical files to meet higher conformity assessment expectations.
Stay Engaged with Consultation
The TGA is currently seeking feedback on draft changes manufacturers should contribute insights, especially where practical implementation challenges exist.
CONCLUSION
Australia’s proposed conformity assessment overhaul signals a bigger regulatory leap, not just a tweak. With stronger alignment to global norms and more emphasis on lifecycle safety, manufacturers should move from a “place‑on‑market” mindset to a continuous compliance lifecycle approach. Those who prepare early upgrading systems and anticipate post‑market commitments will gain competitive advantage and smoother market access. Stay tuned for final implementation dates and detailed guidance once the TGA publishes the official final rules.